Previous 10 | Next 10 |
home / stock / ipsey / ipsey news
Thinly traded nano cap Merrimack Pharmaceuticals ( MACK +6.1% ) is up on almost 30% higher volume, albeit on turnover of only 66K shares, on the heels of its announcement that it has received a $5M milestone payment from Ipsen S.A. ( OTCPK:IPSEY ) triggered by the latter's decision to ad...
Lexicon Pharmaceuticals ( LXRX +5.7% ) is up, albeit on below-average volume, on the heels of a safety review of the initial run-in cohort in a Phase 2 clinical trial, TELE-ABC , evaluating telotristat ethyl, combined with first-line chemo, for the treatment of patients with advanced bi...
Lexicon Pharmaceuticals ( LXRX ) is now in a “hurry up and wait” limbo, as the company waits for clarity on its dispute resolution petition with the FDA regarding Zynquista in Type 1 diabetes and as investors wait for more information and clarity on the clinical profile of Zynq...
Exelixis ( EXEL +0.8% ) announces that Health Canada has approved commercialization partner Ipsen Biopharmaceuticals Canada's ( OTCPK:IPSEY +0.3% ) marketing application for Cabometyx (cabozantinib) for the treatment of hepatocellular carcinoma in patients who have previously re...
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191104006077/en/ Dr. Howard Mayer, Executive Vice-President and Head of Research and Development, effective December 1st, 2019 (Photo: Business Wire) Ipsen (...
Mayroy files a request with the AMF for a waiver to the obligation to file a public offer Regulatory News: The Board of Directors of Ipsen (Euronext: IPN; ADR: IPSEY) takes note of the proposed demerger of Mayroy and the internal reclassification of its Ipsen shares, resulting in a...
The following slide deck was published by Ipsen S.A. in conjunction with their 2019 Q3 earnings Read more ...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced sales for the third quarter of 2019. Financial highlights Q3 2019 Group sales growth of +16.0% as reported and +14.5% 1 at constant exchange rates and cons...
-- Expands Ipsen’s Rare Diseases portfolio to include BLU-782, a highly selective investigational ALK2 inhibitor for the treatment of FOP -- -- Accelerates global development of BLU-782 through Ipsen’s clinical expertise in rare diseases and global infrastructure -- ...
Nestle S.A. ( OTCPK:NSRGY ) subsidiary Galderma announces positive results from a Phase 2 clinical trial evaluating QM1114, its ready-to-use liquid formulation of botulinum toxin type A, for the treatment of glabellar lines (frown lines). More news on: Nestlé S.A., Allergan plc, Evo...
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...